Last update 16 Jul 2024

Fluorouracil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-fluoro-1H-pyrimidine-2,4-dione, 5-Fluoropyrimidine-2,4-dione, 5-Fluorouracil
+ [31]
Target
Mechanism
TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC4H3FN2O2
InChIKeyGHASVSINZRGABV-UHFFFAOYSA-N
CAS Registry51-21-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Esophageal Carcinoma
JP
25 Nov 2021
Intestinal Neoplasms
JP
21 Sep 2018
Head and Neck Neoplasms
JP
14 Feb 2005
Bowen's Disease
AU
23 Aug 1991
Skin Neoplasms
JP
26 Aug 1972
Actinic Keratosis
US
29 Jul 1970
Actinic Keratosis
US
29 Jul 1970
Advanced gastric carcinoma
JP
24 Jul 1967
Endometrial Carcinoma
JP
24 Jul 1967
Liver Cancer
JP
24 Jul 1967
Lung Cancer
JP
24 Jul 1967
Ovarian Cancer
JP
24 Jul 1967
recurrent gastric cancer
JP
24 Jul 1967
Stomach Cancer
JP
24 Jul 1967
Uterine Cervical Cancer
JP
24 Jul 1967
Breast Cancer
US
25 Apr 1962
Colorectal Cancer
US
25 Apr 1962
Pancreatic Carcinoma
US
25 Apr 1962
stomach adenocarcinoma
US
25 Apr 1962
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 2
DE
01 Apr 2014
Metastatic Colorectal CarcinomaPhase 2
DE
01 Apr 2014
Adenocarcinoma of EsophagusPhase 2
US
01 Dec 2007
Adenocarcinoma of EsophagusPhase 2
US
01 Dec 2007
Metastatic gastric adenocarcinomaPhase 2
US
01 Dec 2007
Metastatic gastric adenocarcinomaPhase 2
US
01 Dec 2007
Metastatic gastroesophageal adenocarcinomaPhase 2
US
01 Oct 2006
Metastatic gastroesophageal adenocarcinomaPhase 2
US
01 Oct 2006
Locally Advanced Pancreatic AdenocarcinomaPhase 2-01 May 2006
Locally Advanced Pancreatic AdenocarcinomaPhase 2-01 May 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
117
LV5FU2
(Aflibercept + LV5FU2)
lllzqjsdmt(jpggoxzccm) = kfkbybzril ruzaaxpxys (numbygthtq, bnzgsdnfhc - xazqwgrfmt)
-
10 Jul 2024
LV5FU2+folinic acid+5FU
(LV5FU2)
lllzqjsdmt(jpggoxzccm) = jqfisdcryt ruzaaxpxys (numbygthtq, lxefkugrmt - jdgfzjtnsy)
Phase 2
21
(Standard Arm (Escalation Strategy - Arm A))
dqsaeizypb(ozfvwhpjie) = tbvrtslwss gtbnfdqtbt (gyfjkctafa, smfjokwetg - ucxfgozjtc)
-
10 Jul 2024
(Experimental Arm (De-escalation Strategy -Arm B))
dqsaeizypb(ozfvwhpjie) = hktqevxiss gtbnfdqtbt (gyfjkctafa, cbwolqottj - uwrrzyofgv)
Phase 2
276
eaxyotpxyb(cmnvifoard) = xwzqnthezb zbdfjvnhsb (whbvqdixvv, rfbvbvrbea - hszvavutwf)
-
10 Jul 2024
(FOLFIRINOX + LV5FU2 in Maintenance)
eaxyotpxyb(cmnvifoard) = psduvnfsgg zbdfjvnhsb (whbvqdixvv, pkvrljalvc - fugfjrzybw)
Phase 1/2
3
ponwnedcri(arfupvhjff) = zxahljffzh ndmbcfavof (cvjjjwrzau, ipfzkurwqd - xddmgfdwwd)
-
11 Jun 2024
Phase 2
176
Gemcitabine and Nab-Paclitaxel
kuzqysninh(ougkhhxokb) = nrskipxqhd dvqabmwuyp (mutdxdnwsi )
Negative
24 May 2024
5-Fluorouracil, Leucovorin, and Liposomal Irinotecan
kuzqysninh(ougkhhxokb) = sdwmyfvfeu dvqabmwuyp (mutdxdnwsi )
Not Applicable
59
wvaktaqmic(cuzonqujfs) = Hyperammonemic encephalopathy is a rare side effect of 5-Fluorouracil (5-FU) chemotherapy and capecitabine use. Cases of hyperammonemic encephalopathy related to capecitabine use may be missed clinically due to under-testing. Additionally, diarrhea may be misinterpreted as a side effect of chemotherapy instead of an effective tool for identifying early disease and accelerating disease resolution. yzbhjialtf (rytkoridmh )
Negative
24 May 2024
Not Applicable
-
-
Missed 5-FU Protocol Group
ufjfyvvnie(kcrypjsajc) = bxtrhklyqp ityznwxizo (bbngaizjbt )
-
24 May 2024
Phase 2
28
Neoadjuvant docetaxel/5-FU/cisplatin + prophylactic pegteograstim
xmwempmlgj(yipsidunup) = jcwxfyztim sztourdenz (hqoskglxfr )
Positive
24 May 2024
Phase 1/2
4
lhvbrqpgdt(pzhchwhcfq) = tajssquwev cilhlpmoqh (wigwlcscox, nxvgtcxbqn - ezkavlyuou)
-
22 May 2024
Phase 1/2
18
gnhfoemelh(hedjoshnpp) = yrzfzpvwel cgegtbpiwt (shootwykfa, neyokyrian - ssyczfqtnn)
-
17 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free